Sergio Márquez-Peláez

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Health Information

Stem Cell Transplantation

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Jesús Ruiz-Aragón, Sergio Márquez-Peláez
An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines 11 (2) (2023)
Maarten Postma, David Fisman, Norberto D Giglio, Sergio Márquez-Peláez, Van Hung Nguyen, Andrea Pugliese, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F Mould-Quevedo
Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines 11 (6) (2023)
Maarten Postma, David Fisman, Norberto D Giglio, Sergio Márquez-Peláez, Van Hung Nguyen, Andrea Pugliese, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F Mould-Quevedo
Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines 11 (6) (2023)
Jesús Ruiz-Aragón, Sergio Márquez-Peláez
An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines 11 (2) (2023)
Anna Fochesato, Sara Sottile, Andrea Pugliese, Sergio Márquez-Peláez, Hector Toro-Diaz, Ray Gani, Piedad Alvarez, Jesús Ruiz-Aragón
An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population. Vaccines 10 (8) (2022)
Jesús Ruiz-Aragón, Sergio Márquez-Peláez, Ray Gani, Piedad Alvarez, Richard Guerrero-Luduena
Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain. Vaccines 10 (2) (2022)